1. Erythrocyte Promotion of Platelet Reactivity Decreases the Effectiveness of Aspirin as an Antithrombotic Therapeutic Modality by Juana Valles, M. Teresa Santos, Justo Aznar, Ana Osa, Aida Lago, Juan Cosin, Elena Sanchez, M. Johan Broekman, and Aaron J. Marcus Circulation Volume 97(4):350-355 February 3, 1998 Copyright © American Heart Association, Inc. All rights reserved.

2. Effect of administration of ASA (200 mg daily) on platelet recruitment in patients with IHD. PRP, platelet-erythrocyte suspensions (PRP+RBC), or WB were stimulated with collagen (1 μg/mL) and centrifuged to obtain a cell-free releasate. Juana Valles et al. Circulation. 1998;97:350-355 Copyright © American Heart Association, Inc. All rights reserved.

3. Effect of administration of 300 mg/d ASA on platelet recruitment in patients CVD. PRP, platelet- erythrocyte suspensions (PRP+RBC), or WB were treated as in Fig 1 (see “Methods”). Juana Valles et al. Circulation. 1998;97:350-355 Copyright © American Heart Association, Inc. All rights reserved.

4. Effect of long-term administration of intermediate doses of aspirin (200–300 mg/day) on platelet recruitment in patients with vascular disease. Juana Valles et al. Circulation. 1998;97:350-355 Copyright © American Heart Association, Inc. All rights reserved.

5. Effect of long-term ASA treatment on platelet 5HT release in patients with vascular disease.14 C- 5HT-radiolabeled PRP, platelet-erythrocyte suspensions, or WB were stimulated with collagen (1 μg/mL), and 5HT release was evaluated in cell-free supernatants (see “Methods”). Juana Valles et al. Circulation. 1998;97:350-355 Copyright © American Heart Association, Inc. All rights reserved.